Outcomes of peripheral blood stem cell transplantation patients from HLA-mismatched unrelated donor with antithymocyte globulin (ATG)-Thymoglobulin versus ATG-Fresenius: a single-center study

Medical Oncology

Volumn 32, Issue 2, 2015, Pages

  Huang, Wenrong ^a,b   Zhao, Xiaoli ^a   Tian, Yamin ^a   Cao, Tingting ^a   Li, Yanfen ^a   Liu, Zhanxiang ^a   Jing, Yu ^a   Wang, Shuhong ^a   Gao, Chunji ^a,b   Yu, Li ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b Hainan Branch of Chinese PLA General Hospital   (China)

Author keywords

ATG Fresenius; ATG Thymoglobulin; HLA mismatched; Peripheral blood stem cell transplantation; Unrelated donor

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATININE; FRESENIUS; NITROGEN; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; UREA; HLA ANTIGEN; LYMPHOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE KIDNEY FAILURE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC REACTION; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; CAUSE OF DEATH; COMPARATIVE EFFECTIVENESS; CREATININE BLOOD LEVEL; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; FEVER; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEART FAILURE; HLA SYSTEM; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; RETROSPECTIVE STUDY; SAFETY; SERUM SICKNESS; SHOCK; SIDE EFFECT; UNRELATED DONORS; UREA NITROGEN BLOOD LEVEL; ADVERSE EFFECTS; ALLOGRAFT; ANTIBODY SPECIFICITY; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; IMMUNOLOGY; INCIDENCE; KAPLAN MEIER METHOD; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ALLOGRAFTS; ANTIBODY SPECIFICITY; ANTILYMPHOCYTE SERUM; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84921046841     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0465-y     Document Type: Article

References (27)

1. Valcárcel D, Sierra J, Wang T, Kan F, Gupta V, Hale GA, et al. One-antigen mismatched related versus HLA-matched unrelated donor hematopoietic stem cell transplantation in adults with acute leukemia: Center for International Blood and Marrow Transplant Research results in the era of molecular HLA typing. Biol Blood Marrow Transplant. 2011;17(5):640–8.
2. Cheuk DK. Optimal stem cell source for allogeneic stem cell transplantation for hematological malignancies. World J Transplant. 2013;3(4):99–112.
3. Anasetti C, Logan BR, Lee SJ, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367(16):1487–96.
4. Bacigalupo A. Matched and mismatched unrelated donor transplantation: is the outcome the same as for matched sibling donor transplantation? Hematology Am Soc Hematol Educ Program. 2012;2012:223–9. doi:10.1182/asheducation-2012.1.223.
5. Pidala J, Tomblyn M, Nishihori T, et al. ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17(8):1237–44.
6. Sheng Z, Ma H, Pang W, Niu S, Xu J. In vivo T-cell depletion with antithymocyte globulins improves overall survival after myeloablative allogeneic stem cell transplantation in patients with hematologic disorders. Acta Haematol. 2013;129(3):146–53.
7. Gaber AO, Monaco AP, Russell JA, Lebranchu Y, Mohty M. Rabbit antithymocyte globulin (thymoglobulin): 25 years and new frontiers in solid organ transplantation and haematology. Drugs. 2010;70(6):691–732.
8. Mueller TF. Thymoglobulin: an immunologic overview. Curr Opin Organ Transplant. 2003;8:305–12.
9. Kumar A, Mhaskar AR, Reljic T, et al. Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review. Leukemia. 2012;26(4):582–8.
10. Penack O, Fischer L, Gentilini C, et al. The type of ATG matters: natural killer cells are influenced differentially by Thymoglobulin Lymphoglobulin and ATG-Fresenius. Transpl Immunol. 2007;18(2):85–7.
11. Ayuk F, Diyachenko G, Zabelina T, et al. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors. Exp Hematol. 2008;36(8):1047–54.
12. Huang WR, Li HH, Gao CJ, et al. Unmanipulated HLA-mismatched/haploidentical peripheral blood stem cell transplantation for high-risk hematologic malignancies. Transfusion. 2012;52(6):1354–62.
13. Sullivan KM. Graft-versus-host disease. In: Blume KG, Forman SJ, Appelbaum FR, editors. Thomas’ hematopoietic Cell transplantation. 3rd ed. Malden: Blackwell Publishing Ltd; 2004. p. 633–64.
14. Shin SH, Yoon JH, Yahng SA, et al. PBSC vs BM grafts with myeloablative conditioning for unrelated donor transplantation in adults with high-risk ALL. Bone Marrow Transplant. 2014;49(6):773–9.
15. Pidala J. Graft-vs-host disease following allogeneic hematopoietic cell transplantation. Cancer Control. 2011;18(4):268–76.
16. Remberger M, Svahn BM, Hentschke P, Lofgren C, Ringden O. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant. 1999;24(8):823–30.
17. Basara N, Baurmann H, Kolbe K, et al. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transplant. 2005;35(10):1011–8.
18. Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001;98(10):2942–7.
19. Schleuning M, Gunther W, Tischer J, Ledderose G, Kolb HJ. Dose-dependent effects of in vivo antithymocyte globulin during conditioning for allogeneic bone marrow transplantation from unrelated donors in patients with chronic phase CML. Bone Marrow Transplant. 2003;32(3):243–50.
20. Remberger M, Svahn BM, Mattsson J, Ringden O. Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation. 2004;78(1):122–7.
21. Duval M, Pedron B, Rohrlich P, et al. Immune reconstitution after haematopoietic transplantation with two different doses of pre-graft antithymocyte globulin. Bone Marrow Transplant. 2002;30(7):421–6.
22. Meijer E, Cornelissen JJ, Lowenberg B, Verdonck LF. Antithymocyteglobulin as prophylaxis of graft failure and graft-versus-host disease in recipients of partially T-cell-depleted grafts from matched unrelated donors: a dose-finding study. Exp Hematol. 2003;31(11):1026–30.
23. Ayuk F, Diyachenko G, Zabelina T, et al. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008;14(8):913–9.
24. Remberger M, Storer B, Ringden O, Anasetti C. Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant. 2002;29(5):391–7.
25. Finke J, Bethge WA, Schmoor C, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10(9):855–64.
26. Waller EK, Langston AA, Lonial S, et al. Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant. 2003;9(7):460–71.
27. Pihusch R, Holler E, Muhlbayer D, et al. The impact of antithymocyte globulin on short-term toxicity after allogeneic stem cell transplantation. Bone Marrow Transplant. 2002;30(6):347–54.